NetworkNewsBreaks – Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) Closes $48M Follow-On
Mirum Pharmaceuticals (NASDAQ: MIRM), a biopharmaceutical company concentrating on the development and commercialization of novel therapies for debilitating liver diseases, recently closed an underwritten public offering of 2,400,000 shares of its common stock. Sold at a price of $20.00 each, the offering resulted in gross proceeds of $48 million. Additionally, the company granted the underwriters a 30-day option to purchase up to 360,000 shares at the public offering price of $20.00 per share. ROTH Capital Partners served as co-manager for the offering. To view the full press release, visit http://nnw.fm/5xnIc About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a clinical-stage…







